Assured Pharmacy reports spike in Q1 net sales
FRISCO, Texas — Specialty pharmacy provider Assured Pharmacy said first-quarter net sales jumped to $4.4 million for the period ended March 31, an increase of 22.4% from the year-ago quarter.
The 22.4% increase in sales for the quarter primarily was attributed to an increase in the number of prescriptions dispensed during the period, Assured said.
Meanwhile, basic and diluted net loss per share was 12 cents for first quarter 2011 — thanks to the increased sales and reduced operating expenses, as a result of cost-control initiatives — a 78.9% improvement compared with a net loss of 57 cents per share in the same period in 2010.
"We are pleased with our strong year-over-year performance for the first quarter. The improved results reflect continued progress in the implementation of our strategies and provide further validation of our business model as we move forward to the expansion phase of our business cycle," said Robert DelVecchio, Assured Pharmacy CEO.
CDC warns public on zombies. No, really.
ATLANTA — The Centers for Disease Control and Prevention posted an attention-grabbing page Wednesday titled: “Preparedness 101: Zombie Apocalypse.”
“There are all kinds of emergencies out there that we can prepare for,” the CDC stated on the Web page. “Take a zombie apocalypse for example. … You may laugh now, but when it happens you’ll be happy you read this, and hey, maybe you’ll even learn a thing or two about how to prepare for a real emergency.”
In addition to click-through graphic elements — which can be posted to any website, blog, social networking profile or email signature — that link users to more information, the site actually offers advice on emergency supplies, developing a family disaster plan and what to do when under quarantine.
And it’s working — the faux emergency page with real emergency advice has been picked up by a number of mainstream news outlets, including the Wall Street Journal.
Avandia to be available only by mail order in November, FDA asserts
SILVER SPRING, Md. — A controversial GlaxoSmithKline drug for treating Type 2 diabetes no longer will be available through retail pharmacies as of Nov. 18, the Food and Drug Administration announced Wednesday.
Avandia (rosiglitazone) and such related drugs as Avandaryl (rosiglitazone and glimepiride) and Avandamet (rosiglitazone and metformin) will be available only by mail order from specially certified pharmacies and for certain patients, such as those already successfully treated with the drug and those who can’t control their blood sugar with other diabetes drugs and don’t want to use other drugs belonging to the same class as Avandia.
The drug has attracted controversy due to studies showing that it increases the risk of heart attacks in patients taking it. In September 2010, the FDA moved to restrict access to the drug as part of a risk evaluation and mitigation strategy.